Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) SVP Karthik Kuppusamy sold 8,147 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the sale, the senior vice president directly owned 13,510 shares in the company, valued at approximately $2,702,000. This represents a 37.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Quest Diagnostics Stock Down 1.6%
NYSE:DGX opened at $197.07 on Tuesday. The company has a market cap of $21.82 billion, a PE ratio of 21.78, a P/E/G ratio of 2.39 and a beta of 0.59. Quest Diagnostics Incorporated has a twelve month low of $164.65 and a twelve month high of $213.50. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.67. The company’s 50 day moving average is $194.42 and its two-hundred day moving average is $191.45.
Quest Diagnostics (NYSE:DGX – Get Free Report) last released its earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.37 by $0.13. The company had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.83 billion. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. Quest Diagnostics’s revenue was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.94 EPS. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. Analysts anticipate that Quest Diagnostics Incorporated will post 10.72 EPS for the current year.
Quest Diagnostics Announces Dividend
Quest Diagnostics announced that its board has authorized a stock repurchase program on Tuesday, February 10th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 4.7% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.
Hedge Funds Weigh In On Quest Diagnostics
Several large investors have recently made changes to their positions in DGX. Key Financial Inc lifted its stake in shares of Quest Diagnostics by 1,728.6% in the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 121 shares during the period. Quattro Advisors LLC acquired a new position in shares of Quest Diagnostics in the 4th quarter valued at $25,000. JFS Wealth Advisors LLC lifted its stake in shares of Quest Diagnostics by 114.3% in the 4th quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 80 shares during the period. Harbor Investment Advisory LLC lifted its stake in shares of Quest Diagnostics by 113.7% in the 4th quarter. Harbor Investment Advisory LLC now owns 156 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 83 shares during the period. Finally, DV Equities LLC acquired a new position in shares of Quest Diagnostics in the 4th quarter valued at $27,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several analysts have recently commented on the stock. Truist Financial upped their price objective on shares of Quest Diagnostics from $220.00 to $225.00 and gave the company a “hold” rating in a report on Wednesday, April 22nd. Robert W. Baird upped their price objective on shares of Quest Diagnostics from $224.00 to $229.00 and gave the company a “neutral” rating in a report on Wednesday, April 22nd. Wall Street Zen downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Saturday, May 30th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $225.00 price objective on shares of Quest Diagnostics in a report on Tuesday, April 21st. Finally, Barclays upped their price objective on shares of Quest Diagnostics from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Wednesday, April 22nd. Seven research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, Quest Diagnostics presently has a consensus rating of “Moderate Buy” and a consensus price target of $216.58.
Check Out Our Latest Analysis on DGX
Quest Diagnostics Company Profile
Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
Read More
- Five stocks we like better than Quest Diagnostics
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
